Today's Research Reports on IntelliPharmaCeutics International, Centric Health, ProMIS Neurosciences and Theratechnologies
NEW YORK, NY / ACCESSWIRE / September 14, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI Initiates Coverage on:
IntelliPharmaCeutics International Inc.
https://rdinvesting.com/news/?ticker=IPCI.TO
Centric Health Corporation
https://rdinvesting.com/news/?ticker=CHH.TO
ProMIS Neurosciences, Inc.
https://rdinvesting.com/news/?ticker=PMN.TO
Theratechnologies Inc.
https://rdinvesting.com/news/?ticker=TH.TO
IntelliPharmaCeutics International’s stock had no change Thursday, to close the day at $0.435. The stock recorded a trading volume of 324 shares, which was below its three months average volume of 9,230 shares. In the last year, IntelliPharmaCeutics International's shares have traded in a range of 0.31 - 1.58. The share price has gained 40.32% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.394 is lower than its 200-day moving average of $0.573. Shares of IntelliPharmaCeutics International have fallen approximately 55.56 percent year-to-date.
Access RDI's IntelliPharmaCeutics International Inc. Research Report at:
https://rdinvesting.com/news/?ticker=IPCI.TO
On Thursday, shares of Centric Health recorded a trading volume of 354,263 shares, which was below the three months average volume of 356,563 shares. The stock ended the day 8.06% lower at $0.285. The share price has fallen 64.38% from its 52 week high with a 52 week trading range of 0.20 - 0.80. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.28 is lower than its 200-day moving average of $0.35. Shares of Centric Health have fallen approximately 46.15 percent year-to-date.
Access RDI's Centric Health Corporation Research Report at:
https://rdinvesting.com/news/?ticker=CHH.TO
ProMIS Neurosciences’ stock had no change Thursday, to close the day at $0.29. The stock recorded a trading volume of 108,368 shares, which was below its three months average volume of 246,087 shares. In the last year, ProMIS Neurosciences' shares have traded in a range of 0.18 - 0.73. The share price has gained 61.11% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.31 is lower than its 200-day moving average of $0.38. Shares of ProMIS Neurosciences have gained approximately 45 percent year-to-date.
Access RDI's ProMIS Neurosciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=PMN.TO
On Thursday, shares of Theratechnologies recorded a trading volume of 449,628 shares, which was above the three months average volume of 180,500 shares. The stock ended the day 4.39% lower at $8.94. The share price has fallen 39.39% from its 52 week high with a 52 week trading range of 4.96 - 14.75. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $9.60 is lower than its 200-day moving average of $10.61. Shares of Theratechnologies have gained approximately 24.51 percent year-to-date.
Access RDI's Theratechnologies Inc. Research Report at:
https://rdinvesting.com/news/?ticker=TH.TO
Our Actionable Research on IntelliPharmaCeutics International Inc. (TSX:IPCI.TO), Centric Health Corporation (TSX:CHH.TO), ProMIS Neurosciences, Inc. (TSX:PMN.TO) and Theratechnologies Inc. (TSX:TH.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
https://www.accesswire.com/511955/Todays-Research-Reports-on-IntelliPharmaCeutics-International-Centric-Health-ProMIS-Neurosciences-and-Theratechnologies
